Neuronetics Stock Price, News & Analysis

Neuronetics, Inc. (NASDAQ: STIM) announced the granting of inducement awards to eight new employees, in accordance with NASDAQ Listing Rule 5635(c)(4). The awards consist of 152,939 Restricted Stock Units (RSUs), valued at the closing trading price on Nasdaq, vesting in three equal installments over three years. This move aims to enhance employee retention and incentivize new hires. Neuronetics is focused on improving mental health through innovative treatments, highlighted by its FDA-cleared NeuroStar Advanced Therapy system, which has delivered over four million treatments for depression.

Neuronetics, a leader in neurohealth technology, will release its first quarter 2022 financial results on May 12, 2022, before the market opens. A conference call to discuss these results is scheduled for the same day at 8:30 a.m. ET, accessible via a webcast on their investor relations site. Neuronetics offers the NeuroStar Advanced Therapy system, a leading treatment for major depressive disorder, with over four million treatments delivered. The system is FDA-cleared and backed by extensive clinical research.

Neuronetics (NASDAQ: STIM) and Greenbrook TMS Inc. have entered a five-year commercial agreement to enhance their collaboration in TMS therapy. This agreement allows Greenbrook to exclusively purchase TMS devices from Neuronetics, which will in turn provide marketing support and better pricing. Greenbrook operates 149 treatment centers and has delivered over 790,000 TMS treatments to patients with depression. The partnership aims to increase awareness of NeuroStar therapy and improve patient access, amid rising mental health concerns in America.

Neuronetics, Inc. (NASDAQ: STIM) announced the granting of inducement awards to five new non-executive employees, approved by its Compensation Committee under NASDAQ Listing Rule 5635(c)(4). The company awarded 38,252 Restricted Stock Units (RSUs), valued at the grant date fair value of its common stock, which will vest in three equal installments over three years. Neuronetics is recognized for its NeuroStar Advanced Therapy system, a leading non-invasive treatment for major depressive disorder, with over four million treatments delivered.

Neuronetics, Inc. (NASDAQ: STIM) reported its financial and operational results for Q4 and FY 2021, with Q4 revenue at $15.0 million, surpassing guidance. The company achieved a 12% annual revenue increase, totaling $55.3 million. U.S. treatment session revenue rose by 20% year-over-year, but U.S. NeuroStar Advanced Therapy System sales declined by 22%. Despite positive operational highlights like the MT Cap clearance, increased marketing effectiveness, and improved gross margins, the company faced a net loss of $31.2 million for 2021. For FY 2022, revenue is projected between $58.0 million and $62.0 million.

Neuronetics has announced a $14.5 million investment to enhance education for patients and physicians about NeuroStar® Advanced Therapy for treating major depressive disorder (MDD). Launched on March 3, 2022, the campaign, titled “Tap into a New Possibility,” aims to raise awareness of depression's impact and the treatment options available. The multi-channel strategy seeks to reach individuals struggling with MDD, highlighting the effectiveness of NeuroStar, which has delivered over 4.3 million treatments. This initiative underscores the company’s commitment to mental health.

Neuronetics, Inc. (NASDAQ: STIM) has announced plans to release its fourth quarter and fiscal year 2021 financial and operating results on March 8, 2022. The company aims to improve the quality of life for patients with neurohealth disorders through innovative medical technologies. A conference call is scheduled for the same day at 8:30 a.m. ET, which will be accessible via webcast. As a leader in transcranial magnetic stimulation (TMS) for depression, Neuronetics emphasizes its commitment to enhancing mental health treatments. Further details can be found on their investor relations site.

Neuronetics, Inc. (NASDAQ: STIM) announced an amendment to its term loan agreement with SLR Investment Corp. The adjustments allow for an extension of the interest-only period on the initial Term A Loan to 36 months, alongside a reduction of certain revenue covenants. As per the amendment, Neuronetics opted not to draw additional funds from the agreed tranches. The NeuroStar Advanced Therapy system remains a key asset, having delivered over four million treatments for major depressive disorder, reinforced by comprehensive clinical data.

Neuronetics, Inc. (NASDAQ: STIM) released preliminary unaudited revenue results for the fourth quarter and full year 2021. Fourth quarter revenue is projected between $14.5 to $15.0 million, exceeding prior guidance of $13.0 to $14.0 million. Full year revenue is expected to be $54.8 to $55.3 million, surpassing the earlier forecast of $53.3 to $54.3 million. CEO Keith J. Sullivan highlighted strong treatment volume growth, exclusive agreements with national accounts, and a positive outlook for 2022, emphasizing the company's commitment to expanding the adoption of NeuroStar Advanced Therapy.